Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Corina Dota"'
Autor:
Joanna Parkinson, Jesper Sundell, Dinko Rekić, Karin Nelander, Hans Ericsson, Ahmad Ebrahimi, Corina Dota, Mikael Sunnåker
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 2, Pp n/a-n/a (2024)
Abstract Mitiperstat is a myeloperoxidase inhibitor in clinical development for treatment of patients with heart failure and preserved or mildly reduced ejection fraction, non‐alcoholic steatohepatits and chronic obstructive pulmonary disease. We a
Externí odkaz:
https://doaj.org/article/dff24b86cd934119a37837e539c8eac6
Autor:
Joanna Parkinson, Corina Dota, Christian Källgren, Christer Gottfridsson, Magnus Bjursell, Shira Perl, Thomas Kӧrnicke, Dinko Rekić, Susanne Johansson
Publikováno v:
British Journal of Clinical Pharmacology. 89:1747-1755
This thorough QT/QTc (TQT) study was conducted to evaluate the risk of QT prolongation for verinurad when combined with allopurinol. Verinurad is a novel, urate anion exchanger 1 inhibitor that reduces serum urate levels by promoting urinary excretio
Autor:
Dinko Rekić, Ivan Azarov, Jane Knöchel, Victor Sokolov, Catarina Nilsson, Linda Wernevik, David Han, Tina Rydén‐Bergsten, Ahmad Ebrahimi, Corina Dota, Björn Carlsson
Publikováno v:
British Journal of Clinical Pharmacology. 88:4839-4844
AZD8233 is a proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotide under development for treatment of hypercholesterolaemia. A prespecified concentration-QT analysis was performed based on data from a single ascending dose s
Autor:
Veronika Voronova, Corina Dota, S. Y. Amy Cheung, Gaia Schiavon, Joanna Parkinson, Brijesh Maroj, Philip Delff, Marie Cullberg, Dinko Rekić
Publikováno v:
British Journal of Clinical Pharmacology. 88:858-864
Pharmacokinetics-matched digital electrocardiogram data (n = 503 measurements from 180 patients) collected in a first-in-human, multi-part, dose-escalation (from 80 to 800 mg) and dose expansion (at 480 mg) phase 1 study in patients with advanced sol
Autor:
Yan Li, Torbjörn Vik, Dana Ghiorghiu, Corina Dota, Remy B. Verheijen, Stephen Walker, Ghada F. Ahmed, Tarjinder Sahota, Ronald Goldwater, Anders Mellemgaard, Weili Yan
Publikováno v:
Clinical Pharmacology in Drug Development. 10:521-534
Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, bioavailable, selective MET-tyrosine kinase inhibitor. This randomized, double-blind, 3-way, crossover phase 1 study of savolitinib versus moxifloxacin (positive control) and placebo-evaluated ef
Autor:
Nicolas Couvreur, Charles Benson, Jean-Michel Guillon, Yoshiko Okai, Armando Lagrutta, Todd Wisialowski, Michael G. Rolf, Ard Teisman, C. Michael Foley, Hugo M. Vargas, Jean-Pierre Valentin, Maki Ito, Michael J. Engwall, Khuram W. Chaudhary, Gary Gintant, David J. Gallacher, Takashi Yoshinaga, Andrea Greiter-Wilke, Corina Dota, Paul Levesque, Katsuyoshi Chiba, Amy Pointon, Stephen Jenkinson, Anthony Bahinski, Martin Traebert, Brian Guth, Eric Martel, Alan S. Bass, Christa Hegele‐Hartung, William E. Achanzar, Ravikumar Peri, Herbert M. Himmel, Yusheng Qu, Derek J. Leishman
Publikováno v:
Clinical Pharmacology and Therapeutics
Defining an appropriate and efficient assessment of drug‐induced corrected QT interval (QTc) prolongation (a surrogate marker of torsades de pointes arrhythmia) remains a concern of drug developers and regulators worldwide. In use for over 15 years
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performance
Autor:
Corina Dota, Rhianna O'Sullivan, Gael Cantet, Alienor Berges, Vincent F. S. Dubois, Guillemette E. Benoist, Stein Schalkwijk, Joanna Parkinson, Dinko Rekić, Sarit Cohen-Rabbie, Helen Tomkinson
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(3)
AIMS Concentration-QT modelling (C-QTc) of first-in-human data has been rapidly adopted as the primary evaluation of QTc interval prolongation risk. Here, we evaluate the performance of C-QTc in early oncology settings (i.e., patients, no placebo or
Autor:
Jean-Philippe Couderc, Nenad Sarapa, Charles Benson, Corina Dota, Randy Brown, Mark Ticktin, Jim Ferry, Wojciech Zareba, Venkat Jarugula, Borje Darpo, Catherine Ortemann-Renon, Steve Riley, Thuan G. Pham, Georg Ferber, James Keirns
Publikováno v:
The Journal of Clinical Pharmacology. 60:125-139
The JTpeak interval has been proposed as a new biomarker to demonstrate mixed ion channel effects, potentially leading to reduced late-stage electrocardiogram (ECG) monitoring for mildly QT-prolonging drugs. ECG waveforms from the IQ-CSRC study were
Autor:
Alienor Berges, Sarit Cohen-Rabbie, Corina Dota, Helen Tomkinson, Joanna Parkinson, Dinko Rekić
Publikováno v:
Journal of clinical pharmacologyReferences. 61(8)
The International Conference on Harmonisation (ICH) E14 guidance provides recommendations to assess the potential of a drug to delay cardiac repolarization (QT prolongation), including general guidelines for cases in which a conventional thorough QT
Autor:
Å. M. Kragh, T. Vik, Teresa Collins, Chris Pollard, Joanna Parkinson, Cecilia Arfvidsson, Corina Dota, S. Y. A. Cheung, Bengt Hamrén, Helen Tomkinson, U. Wählby-Hamrén, Linnéa Bergenholm
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 45:365-381
Drugs can affect the cardiovascular (CV) system either as an intended treatment or as an unwanted side effect. In both cases, drug-induced cardiotoxicities such as arrhythmia and unfavourable hemodynamic effects can occur, and be described using math